← Back to Search

Interleukin-1 inhibitor

Rilonacept for Autoimmune Hearing Loss

Phase < 1
Waitlist Available
Led By Stanley B Cohen, MD
Research Sponsored by Stanley Cohen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights

Summary

This trial is testing rilonacept, a drug that reduces inflammation, on patients with progressive hearing loss in both ears. The goal is to see if reducing inflammation can help improve or stabilize their hearing.

Eligible Conditions
  • Autoimmune Hearing Loss

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Improvement in hearing in comparison to baseline values
Secondary study objectives
Pt reported evaluation of auditory acuity
Quality of Life assessment
Tinnitus evaluation
+1 more

Side effects data

From 2014 Phase 4 trial • 42 Patients • NCT01663103
14%
upper respiratory infection
5%
Injection site reaction
5%
Neck abscess/pyomyositis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Rilonacept
Placebo

Trial Design

1Treatment groups
Experimental Treatment
Group I: RilonaceptExperimental Treatment1 Intervention
A loading dose of 320 mg the first dose then be a once-weekly injection of 160 mg for 24 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rilonacept
FDA approved

Find a Location

Who is running the clinical trial?

Regeneron PharmaceuticalsIndustry Sponsor
655 Previous Clinical Trials
385,257 Total Patients Enrolled
Stanley CohenLead Sponsor
Stanley B Cohen, MDPrincipal InvestigatorMetroplex Clinical Research Center
~1 spots leftby Oct 2025